23 , 24 , 26 , 28 , 38 In patients treated with erenumab, there was a nominally significant reduction in weekly migraine days as early as Week 1 in the pooled post hoc analysis of patients with episodic or chronic migraine. 21 , 22 In the pooled analysis of the PREEMPT clinical trials 39 , 40 for onabotulinumtoxinA in patients with chronic migraine, 12 there was a reduction in headache and migraine days as early as Week 1 when compared to placebo at the end of Week 4 post-treatment.
← all excerpts
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review.
1
—
—